Download PDF
Semin Neurol 2014; 34(05): 591-596
DOI: 10.1055/s-0034-1396012
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Spasticity and Intrathecal Baclofen

Erin Furr-Stimming
1   Department of Neurology, Movement Disorders Division, University of Texas Medical School, Houston, Texas
,
Allison M. Boyle
1   Department of Neurology, Movement Disorders Division, University of Texas Medical School, Houston, Texas
,
Mya C. Schiess
1   Department of Neurology, Movement Disorders Division, University of Texas Medical School, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
17 December 2014 (online)

    Permissions and Reprints

Abstract

Severe spastic tone and/or spastic hypertonia can be the most disabling consequences of a neurologic insult, resulting from an excess of muscle tone. Baclofen, a GABA-B agonist, is one of the most widely used drugs in treating abnormal or disabling spastic tone. However, the effectiveness of baclofen taken orally is often limited by its systemic side effects, including sedation, confusion, and lethargy. Intrathecal baclofen (ITB) delivered by an implanted catheter can work directly at the spinal cord level to reduce spastic tone through presynaptic inhibition. Several decades after Penn and Kroin (1984) proved that continuous infusion of intrathecal baclofen reduced spinal cord spasticity, numerous studies have demonstrated the benefits of ITB therapy and proven its effectiveness in modulating and reducing spastic tone. In this article the authors review current methods of management with ITB therapy; summarize the current knowledge, controversies, and available scientific literature; illustrate through different clinical cases treatment strategies and their outcomes; and lastly, provide a synopsis of current clinical practice in ITB therapy with insights into new therapeutic developments.

Keywords

intrathecal - baclofen - spastic tone - GABA - hypertonia - hyperreflexia - infusion mode
 

  • References

  • 1 Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW ; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111 (1) e89-e97
    CrossrefPubMedGoogle Scholar
  • 2 Ghai A, Garg N, Hooda S, Gupta T. Spasticity - Pathogenesis, prevention and treatment strategies. Saudi J Anaesth 2013; 7 (4) 453-460
    CrossrefPubMedGoogle Scholar
  • 3 Sheean G, McGuire JR. Spastic hypertonia and movement disorders: pathophysiology, clinical presentation, and quantification. PM R 2009; 1 (9) 827-833
    CrossrefPubMedGoogle Scholar
  • 4 Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature 1981; 290 (5802) 149-152
    CrossrefPubMedGoogle Scholar
  • 5 Francisco GE. Intrathecal baclofen therapy for stroke-related spasticity. Top Stroke Rehabil 2001; 8 (1) 36-46
    CrossrefPubMedGoogle Scholar
  • 6 Francisco GE, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003; 84 (8) 1194-1199
    CrossrefPubMedGoogle Scholar
  • 7 Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001; 32 (9) 2099-2109
    CrossrefPubMedGoogle Scholar
  • 8 Knutsson E, Lindblom U, Mårtensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974; 23 (3) 473-484
    CrossrefPubMedGoogle Scholar
  • 9 Müller H, Zierski J, Dralle D, Krauss D, Mutschler E. Pharmacokinetics of intrathecal baclofen. In: Local-Spinal Therapy of Spasticity. Heidelberg, Germany: Springer; 1988: 223-226
    CrossrefGoogle Scholar
  • 10 Albright AL, Shultz BL. Plasma baclofen levels in children receiving continuous intrathecal baclofen infusion. J Child Neurol 1999; 14 (6) 408-409
    CrossrefPubMedGoogle Scholar
  • 11 Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987; 66 (2) 181-185
    CrossrefPubMedGoogle Scholar
  • 12 Ochs GA, Reimann IW, Meinck H-M. Baclofen Intrathekal: Leitfaden für die Praktische Anwendung, Germany: Georg Thieme; 1995
  • 13 Misgeld U, Bijak M, Jarolimek W. A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 1995; 46 (4) 423-462
    CrossrefPubMedGoogle Scholar
  • 14 Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001; 43 (10) 652-657
    CrossrefPubMedGoogle Scholar
  • 15 Pandyan AD, Cameron M, Powell J, Stott DJ, Granat MH. Contractures in the post-stroke wrist: a pilot study of its time course of development and its association with upper limb recovery. Clin Rehabil 2003; 17 (1) 88-95
    CrossrefPubMedGoogle Scholar
  • 16 Twitchell TE. The restoration of motor function following hemiplegia in man. Brain 1951; 74 (4) 443-480
    CrossrefPubMedGoogle Scholar
  • 17 Ward NS, Brown MM, Thompson AJ, Frackowiak RS. Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain 2003; 126 (Pt 11) 2476-2496
    CrossrefPubMedGoogle Scholar
  • 18 O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. Brain 1996; 119 (Pt 5) 1737-1749
    CrossrefPubMedGoogle Scholar
  • 19 Schiess MC, Oh IJ, Stimming EF , et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation 2011; 14 (1) 38-45 , discussion 45
    CrossrefPubMedGoogle Scholar
  • 20 Graham LA. Management of spasticity revisited. Age Ageing 2013; 42 (4) 435-441
    CrossrefPubMedGoogle Scholar
  • 21 Pandyan AD, Gregoric M, Barnes MP , et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005; 27 (1-2) 2-6
    CrossrefPubMedGoogle Scholar
  • 22 Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67 (2) 206-207
    PubMedGoogle Scholar
  • 23 Jose A, Luciano P, Vicente V, Juan Marcos AS, Gustavo F-C. Role of catheter's position for final results in intrathecal drug delivery. Analysis based on CSF dynamics and specific drugs profiles. Korean J Pain 2013; 26 (4) 336-346
    CrossrefPubMedGoogle Scholar
  • 24 Rawlins PK. Intrathecal baclofen therapy over 10 years. J Neurosci Nurs 2004; 36 (6) 322-327
    CrossrefPubMedGoogle Scholar
  • 25 Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 1 (8385) 1078
    PubMedGoogle Scholar
  • 26 Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil 1996; 77 (5) 461-466
    CrossrefPubMedGoogle Scholar
  • 27 Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 1999; 45 (4) 833-836 , discussion 836–837
    CrossrefPubMedGoogle Scholar
  • 28 Albright AL. Spasticity and movement disorders in cerebral palsy. J Child Neurol 1996; 11 (1) (Suppl. 01) S1-S4
    CrossrefPubMedGoogle Scholar
  • 29 Mathur SN, Chu SK, McCormick Z, Chang Chien GC, Marciniak CM. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. PM R 2014; 6 (6) 506-513 , e1
    CrossrefPubMedGoogle Scholar
  • 30 Saval A, Chiodo AE. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin. J Spinal Cord Med 2010; 33 (1) 16-21
    PubMedGoogle Scholar
  • 31 Dietz V, Sinkjaer T. Spastic movement disorder: impaired reflex function and altered muscle mechanics. Lancet Neurol 2007; 6 (8) 725-733
    CrossrefPubMedGoogle Scholar
  • 32 Draulans N, Vermeersch K, Degraeuwe B , et al. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil 2013; 27 (12) 1137-1143
    CrossrefPubMedGoogle Scholar
  • 33 Rekand T, Grønning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 2011; 43 (6) 511-514
    CrossrefPubMedGoogle Scholar
  • 34 Ridley B, Rawlins PK. Intrathecal baclofen therapy: ten steps toward best practice. J Neurosci Nurs 2006; 38 (2) 72-82
    CrossrefPubMedGoogle Scholar
  • 35 Gilmartin R, Bruce D, Storrs BB , et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000; 15 (2) 71-77
    CrossrefPubMedGoogle Scholar
  • 36 Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus 2006; 21 (2) e3
    PubMedGoogle Scholar
  • 37 Turner M, Nguyen HS, Cohen-Gadol AA. Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations. J Neurosurg Pediatr 2012; 10 (4) 315-319
    CrossrefPubMedGoogle Scholar